Redeye: Saniona Q2 2023 - One deal achieved
Redeye returns with an updated view of Saniona following the Q2 report. We reiterate our stance that 2023 will be an important year for the company – most notably to deliver on its goal of non-dilutive incomes. We are overall encouraged by recent events in the company and raise our valuation somewhat.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/